Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.
about
Aspirin in the Chemoprevention of Colorectal Neoplasia: An OverviewProstaglandin E receptor type 4-associated protein interacts directly with NF-kappaB1 and attenuates macrophage activationClinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAITThe Mesothelial Origin of Carcinoma Associated-Fibroblasts in Peritoneal MetastasisThe evolving role of nonsteroidal anti-inflammatory drugs in colon cancer prevention: a cause for optimismProfound Chemopreventative Effects of a Hydrogen Sulfide-Releasing NSAID in the APCMin/+ Mouse Model of Intestinal TumorigenesisNSAID use selectively increases the risk of non-fatal myocardial infarction: a systematic review of randomised trials and observational studiesViral infection, inflammation and schizophreniaThe impact of NSAID treatment on cardiovascular risk - insight from Danish observational data.Adaptation of Bayesian data mining algorithms to longitudinal claims data: coxib safety as an example.Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological preventionAtorvastatin and celecoxib in combination inhibits the progression of androgen-dependent LNCaP xenograft prostate tumors to androgen independenceDose-dependent reduction of 3,2'-dimethyl-4-aminobiphenyl-derived DNA adducts in colon and liver of rats administered celecoxibProstaglandin E2 promotes lung cancer cell migration via EP4-betaArrestin1-c-Src signalsome.Absence of myeloid COX-2 attenuates acute inflammation but does not influence development of atherosclerosis in apolipoprotein E null miceVitamin D metabolism and action in the prostate: implications for health and disease.Acyl chain-dependent effect of lysophosphatidylcholine on endothelial prostacyclin productionPrimary prevention of colorectal cancer.Chemoprevention in patients with genetic risk of colorectal cancersCyclooxygenase- and lipoxygenase-mediated DNA damage.Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis.Clinical end points for developing pharmaceuticals to manage patients with a sporadic or genetic risk of colorectal cancerNonsteroidal anti-inflammatory drugs: effects on mortality after colorectal cancer diagnosis.Chemopreventive effects of berberine on intestinal tumor development in Apcmin/+ miceAnimal models of colitis-associated carcinogenesis.Risk of cardiovascular events in a randomized placebo-controlled, double-blind trial of difluoromethylornithine plus sulindac for the prevention of sporadic colorectal adenomasCelecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs.Clinical trials update: Tertiary prevention of colorectal cancer.In vitro and in vivo inhibitory effect of three Cox-2 inhibitors and epithelial-to-mesenchymal transition in human bladder cancer cell lines.The role of COX-2 in intestinal inflammation and colorectal cancerCelecoxib and acetylbritannilactone interact synergistically to suppress breast cancer cell growth via COX-2-dependent and -independent mechanismsCoxibs and other nonsteroidal anti-inflammatory drugs in animal models of cancer chemoprevention.Consensus about managing gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs?Comparison between 200 mg QD and 100 mg BID oral celecoxib in the treatment of knee or hip osteoarthritis.Inhibition of the Prostaglandin Transporter PGT Lowers Blood Pressure in Hypertensive Rats and MiceConstitutive overexpression of the oncogene Rac1 in the airway of recurrent respiratory papillomatosis patients is a targetable host-susceptibility factor.Disruption of the 5-lipoxygenase pathway attenuates atherogenesis consequent to COX-2 deletion in mice.Treatment strategies for osteoarthritis patients with pain and hypertension.COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARdelta activationAcyl chain-dependent effect of lysophosphatidylcholine on cyclooxygenase (COX)-2 expression in endothelial cells.
P2860
Q22306433-E0FCBA82-15C1-4636-8FBB-1FBEB34B9459Q24313175-0822A18A-6775-4D5A-8D87-063CB7147EF7Q24602794-69D71F19-AC6A-40F0-86B6-EE1EA6BB9CF5Q26783022-8F94AA58-0393-4AA3-89ED-3F52A5E87157Q28087427-24D0E5D8-6C3F-4CC5-B1BC-F695B3B1EC0CQ28550361-28413258-2260-47EC-9751-29282E034F40Q28742977-AC737EEC-0B50-44BE-9EEF-95B7B91C2708Q30440507-E90390D5-5BB9-484B-BC60-ABF67BE85B49Q30791071-2427E848-B577-45DB-97F7-0D7844048B29Q33363061-0F7ADE8D-77B0-4A6A-9A0A-8AC71D35262EQ33574045-5252190A-227E-4625-A1EB-2B04A89A66B6Q33579568-889F2696-0260-481D-87BF-EC34E2210440Q33613090-CC1109E0-4AFA-4F73-A0AA-2F09F96065C6Q33794119-5C61290F-0384-474D-9864-75E7ABE0FBA8Q33808556-C0381108-4E29-4F3A-A229-3938006424EEQ34027269-4BB37C2E-0FB2-431F-B181-E811B79F6B91Q34116412-DF857D1B-CFA4-4DAA-B7D0-72B6F0BC06DAQ34165145-8B58967A-F030-448B-92E3-455CE701C303Q34170508-3B95C543-050B-4C85-A7E8-A93B881AEA67Q34225293-4CCAB593-BDC2-4040-8E44-CE0E51CDAA87Q34247727-A1654D9A-6ADA-49F9-A542-040385B8643EQ34296467-EDAE554C-0DAA-4769-A0A3-424FD5A53646Q34432899-7AAF104F-0FBA-46C0-8821-4DB3AFBD3FF7Q34464171-DA74750F-B62E-4321-B15E-24004511AC2AQ34512820-E33FCE93-4D4A-486D-9950-7CB70875D1C6Q34605058-3DA3F121-8F0A-4D46-B633-9FB87815BA97Q34743086-45F9615C-8410-44F1-A469-C9B925C2003DQ34772169-D4B1F606-575C-47B6-95E8-EBAFE10ACDB3Q35212685-3A4461D0-5B75-421F-BC75-CBC88EE50CA6Q35234704-637B2E78-8D37-463E-AF54-6492A02778F8Q35426181-7B3E5ECE-B5AB-44C4-8E6A-74859F112ADEQ35529238-D77A5807-087F-4EF6-9B69-E838A8CB7B1EQ35598707-6257AA9E-E268-448C-A308-B859A2889C5BQ35642358-2FEA56B7-7D0C-45B6-A9BE-0C0FE6DAF0A3Q35677376-3E3654CD-C14B-4210-9462-D4E24948BC19Q35885008-47C72D10-7613-4869-9416-B67CE7756067Q35921866-7BD4999B-B95B-4DB1-8571-C7A109CAF34BQ36059512-D249878A-A0E9-41FC-BC4C-B89D7718DCFDQ36229672-45D0B4A3-3172-49C0-83EB-FC5AF7093E25Q36301300-C8E882D5-5503-4BE3-82DA-4FF7CB8144C7
P2860
Effect of celecoxib on cardiovascular events and blood pressure in two trials for the prevention of colorectal adenomas.
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Effect of celecoxib on cardiov ...... ention of colorectal adenomas.
@ast
Effect of celecoxib on cardiov ...... ention of colorectal adenomas.
@en
Effect of celecoxib on cardiov ...... ention of colorectal adenomas.
@nl
type
label
Effect of celecoxib on cardiov ...... ention of colorectal adenomas.
@ast
Effect of celecoxib on cardiov ...... ention of colorectal adenomas.
@en
Effect of celecoxib on cardiov ...... ention of colorectal adenomas.
@nl
prefLabel
Effect of celecoxib on cardiov ...... ention of colorectal adenomas.
@ast
Effect of celecoxib on cardiov ...... ention of colorectal adenomas.
@en
Effect of celecoxib on cardiov ...... ention of colorectal adenomas.
@nl
P2093
P1433
P1476
Effect of celecoxib on cardiov ...... ention of colorectal adenomas.
@en
P2093
APC and PreSAP Trial Investigators
Ann G Zauber
Bernard Levin
Craig Eagle
Ernest Hawk
John J V McMurray
Marc A Pfeffer
Mariajosé Lechuga
Monica M Bertagnolli
Nadir Arber
P304
P356
10.1161/CIRCULATIONAHA.106.636746
P407
P50
P577
2006-09-01T00:00:00Z